Nemolizumab, also known as Nemluvio, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) to treat moderate to severe prurigo nodularis in adults aged 18 and up, and moderate-to-severe atopic dermatitis (eczema) in adults and adolescents aged 12 and up.
Prurigo nodularis is a long-term skin disorder that results in hard, irritating nodules. Nemolizumab's safety and effectiveness for this illness were proven in two clinical trials conducted on adults (18 years of age and older). In patients with prurigo nodularis under the age of 18, nemolizumab's safety and effectiveness have not been shown.
Nemolizumab has also been authorized for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents (beginning at age 12 and weighing at least 30 kg). When topical treatments alone are unable to adequately control atopic dermatitis, it has been authorized for use in conjunction with topical therapy. Two clinical trials showed efficacy and safety in treating adults and adolescents with moderate-to-severe atopic dermatitis that topical therapies were unable to effectively control.
Nemolizumab’s recommended dosage is 30 mg and it is administered as an injection in a pre-filled pen or pre-filled syringe. The most common side effects with Nemluvio in prurigo nodularis and atopic dermatitis are hypersensitivity and injection site reactions. For the full list of all side effects reported with this medicine, see Section 4 of the Patient Information Leaflet (PIL) or the SmPC available on the MHRA website. As with any medicine, the MHRA will keep the safety and effectiveness of nemolizumab’s under close review. Anyone who suspects they are having a side effect from this medicine are encouraged to talk to their doctor, pharmacist or nurse and report it directly to the MHRA Yellow Card scheme, either through the website (https://yellowcard.mhra.gov.uk/) or by searching the Google Play or Apple App stores for MHRA Yellow Card.
